Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03287414 · ClinicalTrials.gov registry record · Phase 2
Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03287414 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT03287414, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study was to investigate the safety, tolerability and efficacy of VAY736 as potential therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
Interventions
- DRUG Placebo
- DRUG VAY736
- DRUG Standard of Care (SoC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2022-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03287414
The ClinicalTrials.gov registry entry for NCT03287414 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03287414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03287414 about?
NCT03287414 is a clinical study titled "Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis". The purpose of this study was to investigate the safety, tolerability and efficacy of VAY736 as potential therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT03287414?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2017-12-20. Estimated completion is 2022-02-14.
What interventions are being tested in trial NCT03287414?
The interventions under investigation include: Placebo (DRUG), VAY736 (DRUG), Standard of Care (SoC) (DRUG).
Who is sponsoring clinical trial NCT03287414?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.